Previous pre-clinical and clinical studies showed that the decreased ability of the microbiota to produce AhR ligands led to impaired gut barrier functions and AhR agonist activity, ultimately facilitating the development of more severe metabolic syndrome such as high blood pressure, diabetes, and obesity (18). Here, AHR is linked to metabolic syndrome.